Bacteriophage endolysins as novel antimicrobials

Future Microbiology

Volumn 7, Issue 10, 2012, Pages 1147-1171

  Schmelcher, Mathias ^a,b   Donovan, David M ^b   Loessner, Martin J ^a  

^a ETH ZURICH   (Switzerland)

^b AGRICULTURAL RESEARCH SERVICE   (United States)

Author keywords

antimicrobial; bacteriophage; detection; endolysin; lysis; peptidoglycan hydrolase; protein engineering

Indexed keywords

AMIDASE; DISINFECTANT AGENT; ENDOLYSIN; HYBRID PROTEIN; HYDROLASE; UNCLASSIFIED DRUG;

AGRICULTURE; AMINO TERMINAL SEQUENCE; ANTIBIOTIC RESISTANCE; BACILLUS ANTHRACIS; BACTERIOPHAGE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CELL WALL BINDING DOMAIN; CRYSTAL STRUCTURE; ENZYMATIC DEGRADATION; ENZYMATICALLY ACTIVE DOMAIN; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME ENGINEERING; ENZYME SPECIFICITY; ENZYME STRUCTURE; FOOD SAFETY; GENETIC RECOMBINATION; HYDROPHOBICITY; IMMUNOGENICITY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR SIZE; MUTAGENESIS; PHOTOMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; STREPTOCOCCUS EQUI; STREPTOCOCCUS PNEUMONIAE; X RAY CRYSTALLOGRAPHY; ZYMOGRAPHY;

ANTI-INFECTIVE AGENTS; BACTERIOPHAGES; BINDING SITES; BIOLOGICAL AGENTS; ENDOPEPTIDASES; GENETIC ENGINEERING;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; POSIBACTERIA;

EID: 84867073569     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.12.97     Document Type: Review

References (195)

1. Whatmore AM, Reed RH. Determination of turgor pressure in Bacillus subtilis: a possible role for K+ in turgor regulation. J. Gen. Microbiol. 136(12), 2521-2526 (1990).
2. Doyle RJ, Marquis RE. Elastic, flexible peptidoglycan and bacterial cell wall properties. Trends Microbiol. 2(2), 57-60 (1994).
3. Arnoldi M, Fritz M, Bauerlein E, Radmacher M, Sackmann E, Boulbitch A. Bacterial turgor pressure can be measured by atomic force microscopy. Phys. Rev. E Stat. Phys. Plasmas Fluids Relat. Interdiscip. Topics 62(1 Pt B), 1034-1044 (2000).
4. Young R. Bacteriophage lysis: mechanism and regulation. Microbiol. Rev. 56(3), 430-481 (1992).
5. Wang IN, Smith DL, Young R. Holins: the protein clocks of bacteriophage infections. Annu. Rev. Microbiol. 54, 799-825 (2000).
6. Bernhardt TG, Struck DK, Young R. The lysis protein E of phi X174 is a specific inhibitor of the MraY-catalyzed step in peptidoglycan synthesis. J. Biol. Chem. 276(9), 6093-6097 (2001).
7. Xu M, Struck DK, Deaton J, Wang IN, Young R. A signal-arrest-release sequence mediates export and control of the phage P1 endolysin. Proc. Natl Acad. Sci. USA 101(17), 6415-6420 (2004).
8. Sao-Jose C, Parreira R, Vieira G, Santos MA. The N-terminal region of the Oenococcus oeni bacteriophage fOg44 lysin behaves as a bona fide signal peptide in Escherichia coli and as a cis-inhibitory element, preventing lytic activity on oenococcal cells. J. Bacteriol. 182(20), 5823-5831 (2000).
9. Loessner MJ. Bacteriophage endolysins -current state of research and applications. Curr. Opin. Microbiol. 8(4), 480-487 (2005).
10. Russel M, Linderoth NA, Sali A. Filamentous phage assembly: variation on a protein export theme. Gene 192(1), 23-32 (1997).
11. Nelson D, Loomis L, Fischetti VA. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc. Natl Acad. Sci. USA 98(7), 4107-4112 (2001).
12. Kanamaru S, Ishiwata Y, Suzuki T, Rossmann MG, Arisaka F. Control of bacteriophage T4 tail lysozyme activity during the infection process. J. Mol. Biol. 346(4), 1013-1020 (2005).
13. Moak M, Molineux IJ. Peptidoglycan hydrolytic activities associated with bacteriophage virions. Mol. Microbiol. 51(4), 1169-1183 (2004).
14. Lavigne R, Briers Y, Hertveldt K, Robben J, Volckaert G. Identification and characterization of a highly thermostable bacteriophage lysozyme. Cell. Mol. Life Sci. 61(21), 2753-2759 (2004).
15. Delbrück M. The growth of bacteriophage and lysis of the host. J. Gen. Physiol. 23(5), 643-660 (1940).
16. Loessner MJ, Wendlinger G, Scherer S. Heterogeneous endolysins in Listeria monocytogenes bacteriophages: a new class of enzymes and evidence for conserved holin genes within the siphoviral lysis cassettes. Mol. Microbiol. 16(6), 1231-1241 (1995).
17. Schmelcher M, Shabarova T, Eugster MR et al. Rapid multiplex detection and differentiation of Listeria cells by use of fluorescent phage endolysin cell wall binding domains. Appl. Environ. Microbiol. 76(17), 5745-5756 (2010).
18. Borysowski J, Weber-Dabrowska B, Gorski A. Bacteriophage endolysins as a novel class of antibacterial agents. Exp. Biol. Med. (Maywood) 231(4), 366-377 (2006).
19. Lopez R, Garcia E, Garcia P, Garcia JL. The pneumococcal cell wall degrading enzymes: a modular design to create new lysins? Microb. Drug Resist. 3(2), 199-211 (1997).
20. Shen Y, Mitchell MS, Donovan DM, Nelson DC. Phage-based enzybiotics. In: Bacteriophages in Health and Disease. Hyman P, Abedon ST (Eds). CABI, UK (2012) (In press).
21. Low LY, Yang C, Perego M, Osterman A, Liddington R. Role of net charge on catalytic domain and influence of cell wall binding domain on bactericidal activity, specificity, and host range of phage lysins. J. Biol. Chem. 286(39), 34391-34403 (2011).
22. Vollmer W, Joris B, Charlier P, Foster S. Bacterial peptidoglycan (murein) hydrolases. FEMS Microbiol. Rev. 32(2), 259-286 (2008).
23. Schindler CA, Schuhardt VT. Lysostaphin: a new bacteriolytic agent for the staphylococcus. Proc. Natl Acad. Sci. USA 51, 414-421 (1964).
24. Fischetti VA. Bacteriophage lytic enzymes: novel anti-infectives. Trends Microbiol. 13(10), 491-496 (2005).
25. Fischetti VA. Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens. Int. J. Med. Microbiol. 300(6), 357-362 (2010).
26. Nelson DC, Schmelcher M, Rodriguez-Rubio L et al. Endolysins as antimicrobials. Adv. Virus Res. 83, 299-365 (2012).
27. Fenton M, Ross P, McAuliffe O, O'Mahony J, Coffey A. Recombinant bacteriophage lysins as antibacterials. Bioeng. Bugs 1(1), 9-16 (2010).
28. Donovan DM. Bacteriophage and peptidoglycan degrading enzymes with antimicrobial applications. Recent Pat. Biotechnol. 1(2), 113-122 (2007).
29. Donovan DM, Becker SC, Dong S, Baker JR, Foster-Frey J, Pritchard DG. Peptidoglycan hydrolase enzyme fusions for treating multi-drug resistant pathogens. Biotech. Int. 21(2), 6-10 (2009).
30. O'Flaherty S, Ross RP, Coffey A. Bacteriophage and their lysins for elimination of infectious bacteria. FEMS Microbiol. Rev. 33(4), 801-819 (2009).
31. Hermoso JA, Garcia JL, Garcia P. Taking aim on bacterial pathogens: from phage therapy to enzybiotics. Curr. Opin. Microbiol. 10(5), 461-472 (2007).
32. Lopez R, Garcia E. Recent trends on the molecular biology of pneumococcal capsules, lytic enzymes, and bacteriophage. FEMS Microbiol. Rev. 28(5), 553-580 (2004).
33. Loessner MJ, Kramer K, Ebel F, Scherer S. C-terminal domains of Listeria monocytogenes bacteriophage murein hydrolases determine specific recognition and high-affinity binding to bacterial cell wall carbohydrates. Mol. Microbiol. 44(2), 335-349 (2002).
34. Cheng X, Zhang X, Pflugrath JW, Studier FW. The structure of bacteriophage T7 lysozyme, a zinc amidase and an inhibitor of T7 RNA polymerase. Proc. Natl Acad. Sci. USA 91(9), 4034-4038 (1994).
35. Briers Y, Volckaert G, Cornelissen A et al. Muralytic activity and modular structure of the endolysins of Pseudomonas aeruginosa bacteriophages phiKZ and EL. Mol. Microbiol. 65(5), 1334-1344 (2007).
36. Briers Y, Schmelcher M, Loessner MJ et al. The high-affinity peptidoglycan binding domain of Pseudomonas phage endolysin KZ144. Biochem. Biophys. Res. Commun. 383(2), 187-191 (2009).
37. Zimmer M, Vukov N, Scherer S, Loessner MJ. The murein hydrolase of the bacteriophage phi3626 dual lysis system is active against all tested Clostridium perfringens strains. Appl. Environ. Microbiol. 68(11), 5311-5317 (2002).
38. Seal BS, Fouts DE, Simmons M et al. Clostridium perfringens bacteriophages phiCP39O and phiCP26F: genomic organization and proteomic analysis of the virions. Arch. Virol. 156(1), 25-35 (2011).
39. Loessner MJ, Maier SK, Daubek-Puza H, Wendlinger G, Scherer S. Three Bacillus cereus bacteriophage endolysins are unrelated but reveal high homology to cell wall hydrolases from different bacilli. J. Bacteriol. 179(9), 2845-2851 (1997).
40. Schuch R, Nelson D, Fischetti VA. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 418(6900), 884-889 (2002).
41. Yoong P, Schuch R, Nelson D, Fischetti VA. PlyPH, a bacteriolytic enzyme with a broad pH range of activity and lytic action against Bacillus anthracis. J. Bacteriol. 188(7), 2711-2714 (2006).
42. Becker SC, Foster-Frey J, Stodola AJ, Anacker D, Donovan DM. Differentially conserved staphylococcal SH3b-5 cell wall binding domains confer increased staphylolytic and streptolytic activity to a streptococcal prophage endolysin domain. Gene 443(1-2), 32-41 (2009).
43. O'Flaherty S, Coffey A, Meaney W, Fitzgerald GF, Ross RP. The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including methicillin-resistant Staphylococcus aureus. J. Bacteriol. 187(20), 7161-7164 (2005).
44. Navarre WW, Ton-That H, Faull KF, Schneewind O. Multiple enzymatic activities of the murein hydrolase from staphylococcal phage phi11. Identification of a d-alanylglycine endopeptidase activity. J. Biol. Chem. 274(22), 15847-15856 (1999).
45. Yokoi KJ, Kawahigashi N, Uchida M et al. The two-component cell lysis genes holWMY and lysWMY of the Staphylococcus warneri M phage varphiWMY: cloning, sequencing, expression, and mutational analysis in Escherichia coli. Gene 351, 97-108 (2005).
46. Obeso JM, Martinez B, Rodriguez A, Garcia P. Lytic activity of the recombinant staphylococcal bacteriophage phiH5 endolysin active against Staphylococcus aureus in milk. Int. J. Food Microbiol. 128(2), 212-218 (2008).
47. Pritchard DG, Dong S, Kirk MC, Cartee RT, Baker JR. LambdaSa1 and lambdaSa2 prophage lysins of Streptococcus agalactiae. Appl. Environ. Microbiol. 73(22), 7150-7154 (2007).
48. Garcia P, Garcia JL, Garcia E, Sanchez-Puelles JM, Lopez R. Modular organization of the lytic enzymes of Streptococcus pneumoniae and its bacteriophages. Gene 86(1), 81-88 (1990).
49. Nelson D, Schuch R, Chahales P, Zhu S, Fischetti VA. PlyC: a multimeric bacteriophage lysin. Proc. Natl Acad. Sci. USA 103(28), 10765-10770 (2006).
50. Nelson D, Loomis L, Fischetti VA. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc. Natl Acad. Sci. USA 98(7), 4107-4112 (2001).
51. Vollmer W, Bertsche U. Murein (peptidoglycan) structure, architecture and biosynthesis in Escherichia coli. Biochim. Biophys. Acta 1778(9), 1714-1734 (2008).
52. Schleifer KH, Kandler O. Peptidoglycan types of bacterial cell walls and their taxonomic implications. Bacteriol. Rev. 36(4), 407-477 (1972).
53. Holtje JV, Mirelman D, Sharon N, Schwarz U. Novel type of murein transglycosylase in Escherichia coli. J. Bacteriol. 124(3), 1067-1076 (1975).
54. Thunnissen AM, Dijkstra AJ, Kalk KH et al. Doughnut-shaped structure of a bacterial muramidase revealed by x-ray crystallography. Nature 367(6465), 750-753 (1994).
55. Bateman A, Rawlings ND. The CHAP domain: a large family of amidases including GSP amidase and peptidoglycan hydrolases. Trends Biochem. Sci. 28(5), 234-237 (2003).
56. Zou Y, Hou C. Systematic analysis of an amidase domain CHAP in 12 Staphylococcus aureus genomes and 44 staphylococcal phage genomes. Comput. Biol. Chem. 34(4), 251-257 (2010).
57. Pritchard DG, Dong S, Baker JR, Engler JA. The bifunctional peptidoglycan lysin of Streptococcus agalactiae bacteriophage B30. Microbiology 150, 2079-2087 (2004).
58. Becker SC, Dong S, Baker JR, Foster-Frey J, Pritchard DG, Donovan DM. LysK CHAP endopeptidase domain is required for lysis of live staphylococcal cells. FEMS Microbiol. Lett. 294(1), 52-60 (2009).
59. Bienkowska-Szewczyk K, Lipinska B, Taylor A. The R gene product of bacteriophage lambda is the murein transglycosylase. Mol. Gen. Genet. 184(1), 111-114 (1981).
60. Inouye M, Arnheim N, Sternglanz R. Bacteriophage T7 lysozyme is an N-acetylmuramyl-l-alanine amidase. J. Biol. Chem. 248(20), 7247-7252 (1973).
61. Vollmer W. Structural variation in the glycan strands of bacterial peptidoglycan. FEMS Microbiol. Rev. 32(2), 287-306 (2008).
62. Visweswaran GR, Dijkstra BW, Kok J. Murein and pseudomurein cell wall binding domains of bacteria and archaea -a comparative view. Appl. Microbiol. Biotechnol. 92(5), 921-928 (2011).
63. Ohnuma T, Onaga S, Murata K, Taira T, Katoh E. LysM domains from Pteris ryukyuensis chitinase-A: a stability study and characterization of the chitin-binding site. J. Biol. Chem. 283(8), 5178-5187 (2008).
64. Whisstock JC, Lesk AM. SH3 domains in prokaryotes. Trends Biochem. Sci. 24(4), 132-133 (1999).
65. Ponting CP, Aravind L, Schultz J, Bork P, Koonin EV. Eukaryotic signalling domain homologues in archaea and bacteria. Ancient ancestry and horizontal gene transfer. J. Mol. Biol. 289(4), 729-745 (1999).
66. Fernandez-Tornero C, Lopez R, Garcia E, Gimenez-Gallego G, Romero A. A novel solenoid fold in the cell wall anchoring domain of the pneumococcal virulence factor LytA. Nat. Struct. Biol. 8(12), 1020-1024 (2001).
67. Diaz E, Lopez R, Garcia JL. Chimeric pneumococcal cell wall lytic enzymes reveal important physiological and evolutionary traits. J. Biol. Chem. 266(9), 5464-5471 (1991).
68. Bustamante N, Campillo NE, Garcia E et al. Cpl-7, a lysozyme encoded by a pneumococcal bacteriophage with a novel cell wall-binding motif. J. Biol. Chem. 285(43), 33184-33196 (2010).
69. Gu J, Lu R, Liu X et al. LysGH15B, the SH3b domain of staphylococcal phage endolysin LysGH15, retains high affinity to staphylococci. Curr. Microbiol. 63(6), 538-542 (2011).
70. Gründling A, Schneewind O. Cross-linked peptidoglycan mediates lysostaphin binding to the cell wall envelope of Staphylococcus aureus. J. Bacteriol. 188(7), 2463-2472 (2006).
71. Yoong P, Schuch R, Nelson D, Fischetti VA. Identification of a broadly active phage lytic enzyme with lethal activity against antibioticresistant Enterococcus faecalis and Enterococcus faecium. J. Bacteriol. 186(14), 4808-4812 (2004).
72. Eugster MR, Haug MC, Huwiler SG, Loessner MJ. The cell wall binding domain of Listeria bacteriophage endolysin PlyP35 recognizes terminal GlcNAc residues in cell wall teichoic acid. Mol. Microbiol. 81(6), 1419-1432 (2011).
73. Mayer MJ, Garefalaki V, Spoerl R, Narbad A, Meijers R. Structure-based modification of a Clostridium difficile-targeting endolysin affects activity and host range. J. Bacteriol. 193(19), 5477-5486 (2011).
74. Donovan DM, Lardeo M, Foster-Frey J. Lysis of staphylococcal mastitis pathogens by bacteriophage phi11 endolysin. FEMS Microbiol. Lett. 265(1), 133-139 (2006).
75. Korndörfer IP, Danzer J, Schmelcher M, Zimmer M, Skerra A, Loessner MJ. The crystal structure of the bacteriophage PSA endolysin reveals a unique fold responsible for specific recognition of Listeria cell walls. J. Mol. Biol. 364(4), 678-689 (2006).
76. Porter CJ, Schuch R, Pelzek AJ et al. The 1.6 A crystal structure of the catalytic domain of PlyB, a bacteriophage lysin active against Bacillus anthracis. J. Mol. Biol. 366(2), 540-550 (2007).
77. Sanz JM, Diaz E, Garcia JL. Studies on the structure and function of the N-terminal domain of the pneumococcal murein hydrolases. Mol. Microbiol. 6(7), 921-931 (1992).
78. Sass P, Bierbaum G. Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of Staphylococcus aureus. Appl. Environ. Microbiol. 73(1), 347-352 (2007).
79. Cheng Q, Fischetti VA. Mutagenesis of a bacteriophage lytic enzyme PlyGBS significantly increases its antibacterial activity against group B streptococci. Appl. Microbiol. Biotechnol. 74(6), 1284-1291 (2007).
80. Low LY, Yang C, Perego M, Osterman A, Liddington RC. Structure and lytic activity of a Bacillus anthracis prophage endolysin. J. Biol. Chem. 280(42), 35433-35439 (2005).
81. Gaeng S, Scherer S, Neve H, Loessner MJ. Gene cloning and expression and secretion of Listeria monocytogenes bacteriophage-lytic enzymes in Lactococcus lactis. Appl. Environ. Microbiol. 66(7), 2951-2958 (2000).
82. Sagermann M, Matthews BW. Crystal structures of a T4-lysozyme duplication-extension mutant demonstrate that the highly conserved beta-sheet region has low intrinsic folding propensity. J. Mol. Biol. 316(4), 931-940 (2002).
83. Zhang X, Studier FW. Multiple roles of T7 RNA polymerase and T7 lysozyme during bacteriophage T7 infection. J. Mol. Biol. 340(4), 707-730 (2004).
84. Leung AK, Duewel HS, Honek JF, Berghuis AM. Crystal structure of the lytic transglycosylase from bacteriophage lambda in complex with hexa-N-acetylchitohexaose. Biochemistry 40(19), 5665-5673 (2001).
85. Xu M, Arulandu A, Struck DK, Swanson S, Sacchettini JC, Young R. Disulfide isomerization after membrane release of its SAR domain activates P1 lysozyme. Science 307(5706), 113-117 (2005).
86. Mooers BH, Matthews BW. Extension to 2268 atoms of direct methods in the ab initio determination of the unknown structure of bacteriophage P22 lysozyme. Acta Crystallogr. D Biol. Crystallogr. 62(Pt 2), 165-176 (2006).
87. Hermoso JA, Monterroso B, Albert A et al. Structural basis for selective recognition of pneumococcal cell wall by modular endolysin from phage Cp-1. Structure 11(10), 1239-1249 (2003).
88. Korndörfer IP, Kanitz A, Danzer J, Zimmer M, Loessner MJ, Skerra A. Structural analysis of the l-alanoyl-d-glutamate endopeptidase domain of Listeria bacteriophage endolysin Ply500 reveals a new member of the LAS peptidase family. Acta Crystallogr. D Biol. Crystallogr. 64(Pt 6), 644-650 (2008).
89. Silva-Martin N, Molina R, Angulo I, Mancheno JM, Garcia P, Hermoso JA. Crystallization and preliminary crystallographic analysis of the catalytic module of endolysin from Cp-7, a phage infecting Streptococcus pneumoniae. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 66(Pt 6), 670-673 (2010).
90. Schmelcher M, Waldherr F, Loessner MJ. Listeria bacteriophage peptidoglycan hydrolases feature high thermoresistance and reveal increased activity after divalent metal cation substitution. Appl. Microbiol. Biotechnol. 93(2), 633-643 (2011).
91. Firczuk M, Bochtler M. Folds and activities of peptidoglycan amidases. FEMS Microbiol. Rev. 31(6), 676-691 (2007).
92. Kashyap M, Jagga Z, Das BK, Arockiasamy A, Bhavesh NS. 1H, 13C and 1N NMR assignments of inactive form of P1 endolysin Lyz. Biomol. NMR Assign. 6(1), 87-89 (2012).
93. Henry M, Coffey A, O'Mahony J, Sleator RD. Comparative modelling of LysB from the mycobacterial bacteriophage Ardmore. Bioeng. Bugs 2(2), 88-95 (2011).
94. Sharma RD, Goswami N, Lynn AM, Rajnee, Sharma PK, Jawaid S. A modeled structure for amidase-03 from Bacillus anthracis. Bioinformation 4(6), 242-244 (2009).
95. Loessner MJ, Schneider A, Scherer S. A new procedure for efficient recovery of DNA, RNA, and proteins from Listeria cells by rapid lysis with a recombinant bacteriophage endolysin. Appl. Environ. Microbiol. 61(3), 1150-1152 (1995).
96. Simmons M, Donovan DM, Siragusa GR, Seal BS. Recombinant expression of two bacteriophage proteins that lyse Clostridium perfringens and share identical sequences in the C-terminal cell wall binding domain of the molecules but are dissimilar in their N-terminal active domains. J. Agric. Food Chem. 58(19), 10330-10337 (2010).
97. Loessner MJ, Schneider A, Scherer S. Modified Listeria bacteriophage lysin genes (ply) allow efficient overexpression and one-step purification of biochemically active fusion proteins. Appl. Environ. Microbiol. 62(8), 3057-3060 (1996).
98. Briers Y, Lavigne R, Volckaert G, Hertveldt K. A standardized approach for accurate quantification of murein hydrolase activity in high-throughput assays. J. Biochem. Biophys. Methods 70(3), 531-533 (2007).
99. Daniel A, Euler C, Collin M, Chahales P, Gorelick KJ, Fischetti VA. Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 54(4), 1603-1612 (2010).
100. Loeffler JM, Djurkovic S, Fischetti VA. Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect. Immun. 71(11), 6199-6204 (2003).
101. Kakikawa M, Yokoi KJ, Kimoto H et al. Molecular analysis of the lysis protein Lys encoded by Lactobacillus plantarum phage phig1e. Gene 299(1-2), 227-234 (2002).
102. Donovan DM, Dong S, Garrett W, Rousseau GM, Moineau S, Pritchard DG. Peptidoglycan hydrolase fusions maintain their parental specificities. Appl. Environ. Microbiol. 72(4), 2988-2996 (2006).
103. Loeffler JM, Nelson D, Fischetti VA. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294(5549), 2170-2172 (2001).
104. Jones RN, Barry AL, Gavan TL, Washington JA III. Susceptibility tests: microdilution and macrodilution broth procedures. In: Manual Of Clinical Microbiology. Balows A, Hausler JWJ, Shadomy HJ (Eds). American Society for Microbiology, Washington, DC, USA, 972-977 (1985).
105. Schmelcher M, Powell AM, Becker SC, Camp MJ, Donovan DM. Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing Staphylococcus aureus in murine mammary glands. Appl. Environ. Microbiol. 78(7), 2297-2305 (2012).
106. Kusuma C, Kokai-Kun J. Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 49(8), 3256-3263 (2005).
107. Mitchell GJ, Nelson DC, Weitz JS. Quantifying enzymatic lysis: estimating the combined effects of chemistry, physiology and physics. Phys. Biol. 7(4), 046002 (2010).
108. Levashov PA, Sedov SA, Shipovskov S, Belogurova NG, Levashov AV. Quantitative turbidimetric assay of enzymatic Gramnegative bacteria lysis. Anal. Chem. 82(5), 2161-2163 (2010).
109. Borysowski J, Lobocka M, Miedzybrodzki R, Weber-Dabrowska B, Gorski A. Potential of bacteriophages and their lysins in the treatment of MRSA: current status and future perspectives. BioDrugs 25(6), 347-355 (2011).
110. Spratt BG. Resistance to antibiotics mediated by target alterations. Science 264(5157), 388-393 (1994).
111. Pastagia M, Euler C, Chahales P, Fuentes-Duculan J, Krueger JG, Fischetti VA. A novel chimeric lysin shows superiority to mupirocin for skin decolonization of methicillin-resistant and -sensitive Staphylococcus aureus strains. Antimicrob. Agents Chemother. 55(2), 738-744 (2011).
112. Guariglia-Oropeza V, Helmann JD. Bacillus subtilis sigma(V) confers lysozyme resistance by activation of two cell wall modification pathways, peptidoglycan O-acetylation and D-alanylation of teichoic acids. J. Bacteriol. 193(22), 6223-6232 (2011).
113. Dehart HP, Heath HE, Heath LS, Leblanc PA, Sloan GL. The lysostaphin endopeptidase resistance gene (epr) specifies modification of peptidoglycan cross bridges in Staphylococcus simulans and Staphylococcus aureus. Appl. Environ. Microbiol. 61(4), 1475-1479 (1995).
114. Sugai M, Fujiwara T, Ohta K, Komatsuzawa H, Ohara M, Suginaka H. epr, which encodes glycylglycine endopeptidase resistance, is homologous to femAB and affects serine content of peptidoglycan cross bridges in Staphylococcus capitis and Staphylococcus aureus. J. Bacteriol. 179(13), 4311-4318 (1997).
115. Gründling A, Missiakas DM, Schneewind O. Staphylococcus aureus mutants with increased lysostaphin resistance. J. Bacteriol. 188(17), 6286-6297 (2006).
116. Nau R, Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin. Microbiol. Rev. 15(1), 95-110 (2002).
117. Entenza JM, Loeffler JM, Grandgirard D, Fischetti VA, Moreillon P. Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. Antimicrob. Agents Chemother. 49(11), 4789-4792 (2005).
118. Witzenrath M, Schmeck B, Doehn JM et al. Systemic use of the endolysin Cpl-1 rescues mice with fatal pneumococcal pneumonia. Crit. Care Med. 37(2), 642-649 (2009).
119. Jado I, Lopez R, Garcia E, Fenoll A, Casal J, Garcia P. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J. Antimicrob. Chemother. 52(6), 967-973 (2003).
120. Rashel M, Uchiyama J, Ujihara T et al. Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage phi MR11. J. Infect. Dis. 196(8), 1237-1247 (2007).
121. Ramon J, Saez V, Baez R, Aldana R, Hardy E. PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative. Pharm. Res. 22(8), 1374-1386 (2005).
122. Walsh S, Shah A, Mond J. Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol. Antimicrob. Agents Chemother. 47(2), 554-558 (2003).
123. Kim KP, Cha JD, Jang EH et al. PEGylation of bacteriophages increases blood circulation time and reduces T-helper type 1 immune response. Microb. Biotechnol. 1(3), 247-257 (2008).
124. Resch G, Moreillon P, Fischetti VA. PEGylating a bacteriophage endolysin inhibits its bactericidal activity. AMB Express 1, 29 (2011).
125. Resch G, Moreillon P, Fischetti VA. A stable phage lysin (Cpl-1) dimer with increased antipneumococcal activity and decreased plasma clearance. Int. J. Antimicrob. Agents 38(6), 516-521 (2011).
126. Loeffler JM, Fischetti VA. Synergistic lethal effect of a combination of phage lytic enzymes with different activities on penicillin-sensitive and -resistant Streptococcus pneumoniae strains. Antimicrob. Agents Chemother. 47(1), 375-377 (2003).
127. Becker SC, Foster-Frey J, Donovan DM. The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA. FEMS Microbiol. Lett. 287(2), 185-191 (2008).
128. Djurkovic S, Loeffler JM, Fischetti VA. Synergistic killing of Streptococcus pneumoniae with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin depends on the level of penicillin resistance. Antimicrob. Agents Chemother. 49(3), 1225-1228 (2005).
129. Garcia P, Martinez B, Rodriguez L, Rodriguez A. Synergy between the phage endolysin LysH5 and nisin to kill Staphylococcus aureus in pasteurized milk. Int. J. Food Microbiol. 141(3), 151-155 (2010).
130. Rodriguez-Rubio L, Martinez B, Rodriguez A, Donovan DM, Garcia P. Enhanced staphylolytic activity of the Staphylococcus aureus bacteriophage vB-SauS-phiIPLA88 HydH5 virion-associated peptidoglycan hydrolase: fusions, deletions, and synergy with LysH5. Appl. Environ. Microbiol. 78(7), 2241-2248 (2012).
131. Simmons M, Morales CA, Oakley BB, Seal BS. Recombinant expression of a putative amidase cloned from the genome of Listeria monocytogenes that lyses the bacterium and its monolayer in conjunction with a protease. Probiotics Antimicro. Prot. 4, 1-10 (2012).
132. Zimmer M, Sattelberger E, Inman RB, Calendar R, Loessner MJ. Genome and proteome of Listeria monocytogenes phage PSA: an unusual case for programmed + 1 translational frameshifting in structural protein synthesis. Mol. Microbiol. 50(1), 303-317 (2003).
133. Sheehan MM, Garcia JL, Lopez R, Garcia P. The lytic enzyme of the pneumococcal phage Dp-1: a chimeric lysin of intergeneric origin. Mol. Microbiol. 25(4), 717-725 (1997).
134. Hendrix RW. Bacteriophages: evolution of the majority. Theor. Popul. Biol. 61(4), 471-480 (2002).
135. Diaz E, Lopez R, Garcia JL. Chimeric phage-bacterial enzymes: a clue to the modular evolution of genes. Proc. Natl Acad. Sci. USA 87(20), 8125-8129 (1990).
136. Croux C, Ronda C, Lopez R, Garcia JL. Interchange of functional domains switches enzyme specificity: construction of a chimeric pneumococcal-clostridial cell wall lytic enzyme. Mol. Microbiol. 9(5), 1019-1025 (1993).
137. Croux C, Ronda C, Lopez R, Garcia JL. Role of the C-terminal domain of the lysozyme of Clostridium acetobutylicum ATCC 824 in a chimeric pneumococcal-clostridial cell wall lytic enzyme. FEBS Lett. 336(1), 111-114 (1993).
138. Sheehan MM, Garcia JL, Lopez R, Garcia P. Analysis of the catalytic domain of the lysin of the lactococcal bacteriophage Tuc2009 by chimeric gene assembling. FEMS Microbiol. Lett. 140(1), 23-28 (1996).
139. Wilson DJ, Gonzalez RN, Das HH. Bovine mastitis pathogens in New York and Pennsylvania: prevalence and effects on somatic cell count and milk production. J. Dairy Sci. 80(10), 2592-2598 (1997).
140. Schmelcher M, Tchang VS, Loessner MJ. Domain shuffling and module engineering of Listeria phage endolysins for enhanced lytic activity and binding affinity. Microb. Biotechnol. 4(5), 651-662 (2011).
141. Celia LK, Nelson D, Kerr DE. Characterization of a bacteriophage lysin (Ply700) from Streptococcus uberis. Vet. Microbiol. 130(1-2), 107-117 (2007).
142. Gerova M, Halgasova N, Ugorcakova J, Bukovska G. Endolysin of bacteriophage BFK20: evidence of a catalytic and a cell wall binding domain. FEMS Microbiol. Lett. 321(2), 83-91 (2011).
143. Manoharadas S, Witte A, Blasi U. Antimicrobial activity of a chimeric enzybiotic towards Staphylococcus aureus. J. Biotechnol. 139(1), 118-123 (2009).
144. Loessner MJ, Gaeng S, Wendlinger G, Maier SK, Scherer S. The two-component lysis system of Staphylococcus aureus bacteriophage Twort: a large TTG-start holin and an associated amidase endolysin. FEMS Microbiol. Lett. 162(2), 265-274 (1998).
145. Vaara M. Agents that increase the permeability of the outer membrane. Microbiol. Rev. 56(3), 395-411 (1992).
146. Briers Y, Walmagh M, Lavigne R. Use of bacteriophage endolysin EL188 and outer membrane permeabilizers against Pseudomonas aeruginosa. J. Appl. Microbiol. 110(3), 778-785 (2011).
147. Lu XM, Jin XB, Zhu JY et al. Expression of the antimicrobial peptide cecropin fused with human lysozyme in Escherichia coli. Appl. Microbiol. Biotechnol. 87(6), 2169-2176 (2010).
148. Morita M, Tanji Y, Orito Y, Mizoguchi K, Soejima A, Unno H. Functional analysis of antibacterial activity of Bacillus amyloliquefaciens phage endolysin against Gram-negative bacteria. FEBS Lett. 500(1-2), 56-59 (2001).
149. Morita M, Tanji Y, Mizoguchi K, Soejima A, Orito Y, Unno H. Antibacterial activity of Bacillus amyloliquefaciens phage endolysin without holin conjugation. J. Biosci. Bioeng. 91(5), 469-473 (2001).
150. Orito Y, Morita M, Hori K, Unno H, Tanji Y. Bacillus amyloliquefaciens phage endolysin can enhance permeability of Pseudomonas aeruginosa outer membrane and induce cell lysis. Appl. Microbiol. Biotechnol. 65(1), 105-109 (2004).
151. Lai MJ, Lin NT, Hu A et al. Antibacterial activity of Acinetobacter baumannii phage varphiAB2 endolysin (LysAB2) against both Gram-positive and Gram-negative bacteria. Appl. Microbiol. Biotechnol. 90(2), 529-539 (2011).
152. Dietz GP, Bahr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol. Cell. Neurosci. 27(2), 85-131 (2004).
153. Dietz GP. Cell-penetrating peptide technology to deliver chaperones and associated factors in diseases and basic research. Curr. Pharm. Biotechnol. 11(2), 167-174 (2010).
154. Splith K, Neundorf I. Antimicrobial peptides with cell-penetrating peptide properties and vice versa. Eur. Biophys. J. 40(4), 387-397 (2011).
155. Borysowski J, Gorski A. Fusion to cellpenetrating peptides will enable lytic enzymes to kill intracellular bacteria. Med. Hypotheses 74(1), 164-166 (2010).
156. Garzoni C, Kelley WL. Staphylococcus aureus: new evidence for intracellular persistence. Trends Microbiol. 17(2), 59-65 (2009).
157. Vazquez-Boland JA, Kuhn M, Berche P et al. Listeria pathogenesis and molecular virulence determinants. Clin. Microbiol. Rev. 14(3), 584-640 (2001).
158. Phelps HA, Neely MN. SalY of the Streptococcus pyogenes lantibiotic locus is required for full virulence and intracellular survival in macrophages. Infect. Immun. 75(9), 4541-4551 (2007).
159. Russell BH, Vasan R, Keene DR, Xu Y. Bacillus anthracis internalization by human fibroblasts and epithelial cells. Cell. Microbiol. 9(5), 1262-1274 (2007).
160. Cheng Q, Nelson D, Zhu S, Fischetti VA. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob. Agents Chemother. 49(1), 111-117 (2005).
161. McCullers JA, Karlstrom A, Iverson AR, Loeffler JM, Fischetti VA. Novel strategy to prevent otitis media caused by colonizing Streptococcus pneumoniae. PLoS Pathog. 3(3), e28 (2007).
162. Grandgirard D, Loeffler JM, Fischetti VA, Leib SL. Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitis. J. Infect. Dis. 197(11), 1519-1522 (2008).
163. Fenton M, Casey PG, Hill C et al. The truncated phage lysin CHAP(k) eliminates Staphylococcus aureus in the nares of mice. Bioeng. Bugs 1(6), 404-407 (2010).
164. Gu J, Zuo J, Lei L et al. LysGH15 reduces the inflammation caused by lethal methicillin-resistant Staphylococcus aureus infection in mice. Bioeng. Bugs 2(2), 96-99 (2011).
165. Gu J, Xu W, Lei L et al. LysGH15, a novel bacteriophage lysin, protects a murine bacteremia model efficiently against lethal methicillin-resistant Staphylococcus aureus infection. J. Clin. Microbiol. 49(1), 111-117 (2011).
166. Gupta R, Prasad Y. P-27/HP endolysin as antibacterial agent for antibiotic resistant Staphylococcus aureus of human infections. Curr. Microbiol. 63(1), 39-45 (2011).
167. Callewaert L, Walmagh M, Michiels CW, Lavigne R. Food applications of bacterial cell wall hydrolases. Curr. Opin. Biotechnol. 22(2), 164-171 (2011).
168. Mayer MJ, Narbad A, Gasson MJ. Molecular characterization of a Clostridium difficile bacteriophage and its cloned biologically active endolysin. J. Bacteriol. 190(20), 6734-6740 (2008).
169. Kim WS, Salm H, Geider K. Expression of bacteriophage phiEa1h lysozyme in Escherichia coli and its activity in growth inhibition of Erwinia amylovora. Microbiology 150(Pt 8), 2707-2714 (2004).
170. Turner MS, Waldherr F, Loessner MJ, Giffard PM. Antimicrobial activity of lysostaphin and a Listeria monocytogenes bacteriophage endolysin produced and secreted by lactic acid bacteria. Syst. Appl. Microbiol. 30(1), 58-67 (2007).
171. Stentz R, Bongaerts RJ, Gunning AP, Gasson M, Shearman C. Controlled release of protein from viable Lactococcus lactis cells. Appl. Environ. Microbiol. 76(9), 3026-3031 (2010).
172. Mayer MJ, Payne J, Gasson MJ, Narbad A. Genomic sequence and characterization of the virulent bacteriophage phiCTP1 from Clostridium tyrobutyricum and heterologous expression of its endolysin. Appl. Environ. Microbiol. 76(16), 5415-5422 (2010).
173. Kretzer JW, Lehmann R, Schmelcher M et al. Use of high-affinity cell wall-binding domains of bacteriophage endolysins for immobilization and separation of bacterial cells. Appl. Environ. Microbiol. 73(6), 1992-2000 (2007).
174. Walcher G, Stessl B, Wagner M, Eichenseher F, Loessner MJ, Hein I. Evaluation of paramagnetic beads coated with recombinant Listeria phage endolysin-derived cell-wallbinding domain proteins for separation of Listeria monocytogenes from raw milk in combination with culture-based and real-time polymerase chain reaction-based quantification. Foodborne Pathog. Dis. 7(9), 1019-1024 (2010).
175. Fujinami Y, Hirai Y, Sakai I, Yoshino M, Yasuda J. Sensitive detection of Bacillus anthracis using a binding protein originating from gamma-phage. Microbiol. Immunol. 51(2), 163-169 (2007).
176. Sainathrao S, Mohan KV, Atreya C. Gamma-phage lysin PlyG sequence-based synthetic peptides coupled with Qdotnanocrystals are useful for developing detection methods for Bacillus anthracis by using its surrogates, B. anthracis-Sterne and B. cereus-4342. BMC Biotechnol. 9, 67 (2009).
177. De Vries J, Harms K, Broer I et al. The bacteriolytic activity in transgenic potatoes expressing a chimeric T4 lysozyme gene and the effect of T4 lysozyme on soil-and phytopathogenic bacteria. Syst. Appl. Microbiol. 22(2), 280-286 (1999).
178. Düring K, Porsch P, Fladung M, Lorz H. Transgenic potato plants resistant to the phytopathogenic bacterium Erwinia carotovora. Plant J. 3(4), 587-598 (1993).
179. Oey M, Lohse M, Scharff LB, Kreikemeyer B, Bock R. Plastid production of protein antibiotics against pneumonia via a new strategy for high-level expression of antimicrobial proteins. Proc. Natl Acad. Sci. USA 106(16), 6579-6584 (2009).
180. Oey M, Lohse M, Kreikemeyer B, Bock R. Exhaustion of the chloroplast protein synthesis capacity by massive expression of a highly stable protein antibiotic. Plant J. 57(3), 436-445 (2009).
181. Sordillo LM, Streicher KL. Mammary gland immunity and mastitis susceptibility. J. Mammary Gland Biol. Neoplasia 7(2), 135-146 (2002).
182. Brouillette E, Malouin F. The pathogenesis and control of Staphylococcus aureus-induced mastitis: study models in the mouse. Microbes Infect. 7(3), 560-568 (2005).
183. Bramley AJ, Foster R. Effects of lysostaphin on Staphylococcus aureus infections of the mouse mammary gland. Res. Vet. Sci. 49(1), 120-121 (1990).
184. Oldham ER, Daley MJ. Lysostaphin: use of a recombinant bactericidal enzyme as a mastitis therapeutic. J. Dairy Sci. 74(12), 4175-4182 (1991).
185. Kerr DE, Plaut K, Bramley AJ et al. Lysostaphin expression in mammary glands confers protection against staphylococcal infection in transgenic mice. Nat. Biotechnol. 19(1), 66-70 (2001).
186. Wall RJ, Powell A, Paape MJ et al. Genetically enhanced cows resist intramammary Staphylococcus aureus infection. Nat. Biotechnol. 23(4), 445-451 (2005).
187. Hoopes JT, Stark CJ, Kim HA, Sussman DJ, Donovan DM, Nelson DC. Use of a bacteriophage lysin, PlyC, as an enzyme disinfectant against Streptococcus equi. Appl. Environ. Microbiol. 75(5), 1388-1394 (2009).
188. Van Houdt R, Michiels CW. Biofilm formation and the food industry, a focus on the bacterial outer surface. J. Appl. Microbiol. 109(4), 1117-1131 (2010).
189. Son JS, Lee SJ, Jun SY et al. Antibacterial and biofilm removal activity of a podoviridae Staphylococcus aureus bacteriophage SAP-2 and a derived recombinant cell-walldegrading enzyme. Appl. Microbiol. Biotechnol. 86(5), 1439-1449 (2010).
190. Domenech M, Garcia E, Moscoso M. In vitro destruction of Streptococcus pneumoniae biofilms with bacterial and phage peptidoglycan hydrolases. Antimicrob. Agents Chemother. 55(9), 4144-4148 (2011).
191. Meng X, Shi Y, Ji W et al. Application of a bacteriophage lysin to disrupt biofilms formed by the animal pathogen Streptococcus suis. Appl. Environ. Microbiol. 77(23), 8272-8279 (2011).
192. Panthel K, Jechlinger W, Matis A et al. Generation of Helicobacter pylori ghosts by PhiX protein E-mediated inactivation and their evaluation as vaccine candidates. Infect. Immun. 71(1), 109-116 (2003).
193. Haidinger W, Mayr UB, Szostak MP, Resch S, Lubitz W. Escherichia coli ghost production by expression of lysis gene E and staphylococcal nuclease. Appl. Environ. Microbiol. 69(10), 6106-6113 (2003).
194. Hu S, Kong J, Kong W, Guo T, Ji M. Characterization of a novel LysM domain from Lactobacillus fermentum bacteriophage endolysin and its use as an anchor to display heterologous proteins on the surfaces of lactic acid bacteria. Appl. Environ. Microbiol. 76(8), 2410-2418 (2010).
195. Zhang X, Pan Z, Fang Q, Zheng J, Hu M, Jiao X. An auto-inducible Escherichia coli lysis system controlled by magnesium. J. Microbiol. Methods 79(2), 199-204 (2009).